Evaluation of Lithium as a Glycogen-Synthase-Kinase-3 (GSK-3) Inhibitor in Mild Cognitive Impairment

NCT02601859 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

11

Enrollment

OTHER

Sponsor class

Conditions

Mild Cognitive Impairment

Interventions

DRUG: Lithium Carbonate

Sponsor

University of Dundee

Collaborators

[object Object]